Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. (Q38450276)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2013

Language	Label	Description	Also known as
English	Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.	scientific article published on May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Michael Grimm

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jenny Han

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Pete Griffin

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Christine T Schulteis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Haiying Dong

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jaret Malloy

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

1 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Postgraduate Medicine

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

125

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

47-57

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Standards of medical care in diabetes--2010.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Translating the A1C assay into estimated average glucose values

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

The relationship between health-related quality of life and weight loss

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2660

21 January 2018

Identifiers

10.3810/PGM.2013.05.2660

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23748506%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38450276&oldid=1508860553"